NCT05435339 - A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 4, 2022

Primary Completion Date

May 24, 2024

Study Completion Date

May 24, 2024

Conditions

Solid Tumor, Adult

Interventions

BIOLOGICAL

GEN1053

GEN1053 will be administered as an intravenous (IV) infusion every 3rd week. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.

Trial Locations (5)

37203

Sarah Cannon Research Institute, Nashville

06510

Yale University, New Haven

Unknown

Clinica Universidad de Navarra, Pamplona

Hospital Universitari Vall d'Hebron, Barcelona

Centro Integral Oncologico Clara Campal, Madrid